Share Email Print
cover

Proceedings Paper

Enhanced toxicity in chemotherapeutic drug Epirubicin-treated human bladder cancer cells after pulsed versus continuous irradiation
Author(s): Manfred Steinmetz; Heyke Cacile Diddens
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Previous biophysical investigations1 demonstrated photosensitive propertieB of EPIRUBICIN with sufficient photochemical stability significant radical production and sufficient maintanance of pharmacological properties like intercalation potency Previous in-vitro investigations2 (human bladder cancer line ATCC 5637) demonstrated after drug treatment an enhancement of cytotoxic activity with continoüs irradiation (100 mW/cm2, 20 mm) performed at the wavelength of maximal absorption of the drug Because of a high tissue absorption of this short wavelength combined with decreasing photochemical reactions in deeper tissue, we investigated whether the reaction rate can be increased using pulsed irradiation with an averaged light power of also 100 mW/cm2. As light sources we used an Ar2-laser and an Excimer dye laser system. To simulate different tissue depths we exposed monolayer cells in a first step with different averaged intensities (100, 10, 1 mW/cm2 ) and in a second step we additionally varied drug concentrations (50, 5 ug/ml). 24 h after EPIRUBICIN treatment using a concentration of 50 ug/ml, viability of pulsed irradiated cells was 2 fold less compared to irradiated cells.

Paper Details

Date Published: 1 July 1990
PDF: 7 pages
Proc. SPIE 1203, Photodynamic Therapy: Mechanisms II, (1 July 1990); doi: 10.1117/12.17679
Show Author Affiliations
Manfred Steinmetz, Medizinisches Laserzentrum Luebeck GmbH (Germany)
Heyke Cacile Diddens, Medizinisches Laserzentrum Luebeck GmbH (Germany)


Published in SPIE Proceedings Vol. 1203:
Photodynamic Therapy: Mechanisms II
Thomas J. Dougherty, Editor(s)

© SPIE. Terms of Use
Back to Top